ReviewAnnals of biomedical engineering2026
Graph Neural Networks in Neuroimaging: Current Status and Biostatistical Considerations for Clinical Deployment.
Review in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graph Neural Networks (GNNs) have emerged as a novel paradigm that enables scientists to model complex relational data in medical applications, offering unique advantages over traditional deep learning (DL) approaches for non-Euclidean domains. This paper provides a comprehensive review of current GNN architectures and their healthcare applications, with a focus on functional connectivity analysis, electrical-based diagnostics, and anatomical structure modeling. We analyze the strengths and limitations of spectral and spatial GNN variants, including Graph Convolutional Networks (GCNs), Graph Attention Networks (GATs), and spatio-temporal extensions. Based on our critical assessment of the state-of-the-art innovations, we propose several key directions for medical researchers actively developing GNN technology: (1) Dynamic graph representation learning to capture evolving physiological processes; (2) Multi-modal fusion techniques to integrate heterogeneous biomedical data streams; (3) Uncertainty-aware GNNs for robust clinical decision support; (4) Explainable GNN architectures to enhance interpretability for healthcare practitioners; and (5) Federated GNN frameworks to enable privacy-preserving collaborative learning across institutions. We also introduce a new Temporal Multi-modal Attention Graph Neural Network (TMA-GNN) architecture designed explicitly for longitudinal patient modeling and clinical trial optimization. Our TMA-GNN incorporates multi-head attention mechanisms, temporal edge construction, and a custom loss function to encourage temporal consistency in predictions. We introduce a conceptual framework for the Temporal Multi-modal Attention Graph Neural Network (TMA-GNN), which is designed to support disease progression modeling and clinical trial optimization in neurological disorders. Although the proposed model architecture is technically detailed, this manuscript focuses on the conceptual and methodological design, rather than presenting experimental results. By addressing these proposed research directions, we envision GNNs will play an increasingly pivotal role in precision medicine, disease progression modeling, and treatment personalization.
Indexed as
Identifiers
42029797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.